INBX News

Inhibrx Reports Second Quarter 2025 Financial Results

SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent")...

August 13, 2025Earnings

JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

INBX

May 15, 2025

Inhibrx Q1 EPS $(2.80) Beats $(2.84) Estimate

INBX

May 14, 2025

Inhibrx Biosciences Announces Departure Of Dr. Brendan Eckelman, Co-founder And Chief Scientific Officer And Appoints Dr. Carlos Bais And David Matly to CSO and President, Respectively

INBX

April 1, 2025

Citizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

INBX

March 18, 2025

Inhibrx Q4 Net Income $(47.9)M Or $(3.09) Per Share

INBX

March 17, 2025

Inhibrx Biosciences Q3 EPS $(2.84) Beats $(3.81) Estimate

INBX

November 14, 2024

Inhibrx Announces The Jury Found In Favor Of Inhibrx, Rejecting All Allegations Of Misappropriation Before It, Confirming The Company's Adherence To High Ethical Standards And Innovation In Scientific Research, Reaffirming Its Commitment To Integrity And

INBX

November 4, 2024